Periprocedural Infarction vs. Spontaneous Infarction: Prognostic Significance 

Original title: Comparison of the Prognosis of Spontaneous and Percutaneous Coronary Intervention–Related Myocardial Infarction. Reference: Sergio Leonardi, MD et al. Journal of the American College of Cardiology Vol. 60, No. 22, 2012

Clinical significance of myocardial infarction (MI) associated to coronary angioplasty is a controversial issue worldwide. Most of research on coronary disease includes it as a primary end point weighed against spontaneous MI.

The aim of this study was to compare periprocedural MI vs. spontaneous MI. It analyzed data from 9,087 patients enrolled in two trials that assessed Non ST Segment Elevation Acute Coronary Syndrome (EARLY-ACS and SYNERGY): among these, 893 periprocedural MI and 298 spontaneous MI occurred, and ratios for death at 12 months were compared.

Authors defined periprocedural MI as CK-MB more than 3 times the ULN (upper limit of normal). Adjusted hazard ratios for 1-year death were 1.39 (95% CI: 1.01 to 1.89) for periprocedural MI vs. 5.37 (95% CI: 3.9 to 7.38) for spontaneous MI. In determining the CK-Mb threshold for periprocedural MI to achieve the same prognosis as spontaneous MI, it was observed that elevations of 27 times the ULN were necessary for this to happen.

Conclusion 

The definition of periprocedural infarction used in clinical trials is poorly associated to events, compared to spontaneous infarction.

Editorial Comment:

This study confirms an assumption based on intuition, that cardiac enzymes elevation after angioplasty does not have the same prognosis than Type 1 MI. Further evaluation is required to confirm these results using the new definition of periprocedural MI (a 5 times increase of troponin levels with clinical or electrical signs or ischemia image). Despite the above observations, this study is good news for interventional cardiologists.

Courtesy of María Sol Andres, MD
Hospital Universitario
Fundación Favaloro – Argentina

Dra. María Sol Andrés para SOLACI.ORG

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | Distal Radial vs Transradial Approach in STEMI Patients

The transradial approach (TRA) has been recommended for patients with ST-elevation myocardial infarction (STEMI) for reduced bleeding complications and mortality. However, evidence in support...

STEACS and the Use of Bivalirudin vs. Heparin: In Search of BRIGHT-4 Outcomes

Various studies and registries have previously shown the impact of post-percutaneous coronary intervention (PCI) complications on the survival of patients with ST-segment elevation acute...

Results of the PROSPECT II Substudy: Relationship Between In-Stent or Stent Edge-Related Lipid-Rich Plaque and Adverse Clinical Events After PCI in Patients with MI

The use of drug-eluting stents and the integration of intravascular imaging techniques have reduced the risk of adverse clinical outcomes following percutaneous coronary intervention...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....